Health Condition 1: null- Patient on treatment with Valproic acid or Divalproex Sodium
Conditions
Interventions
None listed
Sponsors
Gujarat Cancer Society Medical College Hospital and Research Centre
Eligibility
Inclusion criteria
Inclusion criteria: Patient should be on treatment with valproic acid or divalproex sodium for a period of 6 months. Patient must be willing to give written informed consent.
Exclusion criteria
Exclusion criteria: 1) Patients already diagnosed with medical illness known to cause thrombocytopenia like vitamin B12 deficiency, active alcohol dependence, renal failure, leukemias and lymphomas, idiopathic thrombocytopenic purpura, thrombotic thrombocytopenic purpura etc. 2) Patients on treatment with other drugs known to cause thrombocytopenia like carbamazapine, phenytoin, diclofenac, ibuprofen, cimetidine, ranitidine, quinine, rifampicin, vancomycin, ampicillin, trimethoprim+sulfamethaxozole, chlorpropamide etc.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary outcome is to find out the percentage of patients on valproic acid treatment developing thrombocytopenia. For the study purpose platelet counts less than 1,50,000/cumm will be defined as thrombocytopeniaTimepoint: Platelets counts of the patients will be measured at baseline (6 months) and monthly thereafter for a period of 3 months i.e. at 7 month, 8 month and 9 month. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary outcome is to study the correlation between the dose of valproic acid used (in mg/kg) with thrombocytopenia (platelet counts less than 1,50,000/cumm).Timepoint: At 6 month, 7 month, 8 month, 9 month. | — |
Countries
India
Contacts
Public ContactDr Harshil Chauhan
Gujarat Cancer Society Medical College, Hospital and Research Centre, Ahmedabad
Outcome results
None listed